Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Carclo on track to hit forecasts, but H1 trading mixed

(Sharecast News) - Carclo's share price dipped on Friday, pausing after an impressive year-to-date performance, after the precision engineering group said its full-year expectations remain unchanged. The company, which operates in the life sciences, aerospace, safety and security markets, said trading since the start of the financial year on 1 April has been in line with management's expectations.

Positive underlying growth in the CTP Manufacturing Solutions division and Speciality business has offset the lower revenue and FX headwinds impacting the Design and Engineering unit, where sales were "slightly lower than anticipated" due to lower customer activity in the US.

However, with EMEA D&E customer project activity ahead of expectations and the previous year, D&E revenues are expected to "partially recover" in the second half.

"The D&E team continues to maintain its focus on asset revitalisation and driving efficiency improvements in our global manufacturing platform which remains critical to delivering our medium-term financial goals," Carclo said.

Shares, which have risen by nearly 150% so far in 2025 to hit levels not seen since mid-2021, were down 6.3% at 60p by 1113 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.